HUP0302951A2 - Eljárás HBV antigének tisztítására, vakcinákban történő alkalmazásra - Google Patents

Eljárás HBV antigének tisztítására, vakcinákban történő alkalmazásra

Info

Publication number
HUP0302951A2
HUP0302951A2 HU0302951A HUP0302951A HUP0302951A2 HU P0302951 A2 HUP0302951 A2 HU P0302951A2 HU 0302951 A HU0302951 A HU 0302951A HU P0302951 A HUP0302951 A HU P0302951A HU P0302951 A2 HUP0302951 A2 HU P0302951A2
Authority
HU
Hungary
Prior art keywords
purification
vaccines
hbv antigens
production
antigen
Prior art date
Application number
HU0302951A
Other languages
English (en)
Inventor
Koen Heyder
Omer Opstel
Peter Schu
Michelle Serantoni
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HUP0302951A2 publication Critical patent/HUP0302951A2/hu
Publication of HUP0302951A3 publication Critical patent/HUP0302951A3/hu
Publication of HU228932B1 publication Critical patent/HU228932B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A találmány tárgyát eljárás képezi vakcina előállítására alkalmazhatóhepatitisz B antigén előállítására, amelynek értelmében az antigéntisztítását cisztein jelenlétében végzik; a találmány továbbá a fentiantigéneket tartalmazó vakcinákra is vonatkozik. Ó
HU0302951A 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines HU228932B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds
PCT/EP2001/009100 WO2002012287A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines

Publications (3)

Publication Number Publication Date
HUP0302951A2 true HUP0302951A2 (hu) 2003-12-29
HUP0302951A3 HUP0302951A3 (en) 2004-10-28
HU228932B1 HU228932B1 (en) 2013-06-28

Family

ID=26244821

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302951A HU228932B1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines

Country Status (36)

Country Link
US (3) US20030235590A1 (hu)
EP (2) EP1307473B1 (hu)
JP (2) JP2004505992A (hu)
KR (1) KR100804922B1 (hu)
CN (1) CN1468256B (hu)
AP (1) AP2003002734A0 (hu)
AR (1) AR030325A1 (hu)
AT (2) ATE412665T1 (hu)
AU (2) AU2001282073B2 (hu)
BG (1) BG66038B1 (hu)
BR (1) BRPI0113155C1 (hu)
CA (2) CA2427475C (hu)
CY (2) CY1106310T1 (hu)
CZ (1) CZ303217B6 (hu)
DE (2) DE60116107T2 (hu)
DK (2) DK1666487T3 (hu)
DZ (1) DZ3470A1 (hu)
EA (1) EA006433B1 (hu)
EG (1) EG25829A (hu)
ES (2) ES2254464T3 (hu)
HK (1) HK1056884A1 (hu)
HU (1) HU228932B1 (hu)
IL (2) IL154301A0 (hu)
MX (1) MXPA03001235A (hu)
MY (1) MY128999A (hu)
NO (1) NO20030635L (hu)
NZ (1) NZ524012A (hu)
OA (1) OA12361A (hu)
PE (1) PE20020287A1 (hu)
PL (1) PL204736B1 (hu)
PT (1) PT1666487E (hu)
SI (2) SI1307473T1 (hu)
SK (2) SK288079B6 (hu)
UA (1) UA79735C2 (hu)
UY (1) UY26882A1 (hu)
WO (1) WO2002012287A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
ATE526036T1 (de) * 2005-08-02 2011-10-15 Novartis Vaccines & Diagnostic Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
EP2097102B1 (en) 2006-09-07 2012-05-30 GlaxoSmithKline Biologicals s.a. Combination vaccine having reduced polio virus antigen quantities
EP2682127A1 (en) 2007-05-02 2014-01-08 GlaxoSmithKline Biologicals S.A. Vaccine
WO2009057699A1 (ja) * 2007-10-30 2009-05-07 Kyocera Corporation 弾性波装置
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
NZ596501A (en) * 2009-05-27 2013-11-29 Glaxosmithkline Biolog Sa Casb7439 constructs
DK2705365T3 (en) * 2011-01-14 2016-10-24 Hal Allergy Holding B V Immunoassay for the direct determination of the antigen content in the products containing the adjuvant-linked antigen particles
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GEP20227386B (en) 2017-07-18 2022-06-10 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
JP2022524007A (ja) 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｂ型肝炎免疫化レジメンおよび組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
KR850001534A (ko) 1983-08-22 1985-03-30 제임스 에프. 나우톤 형질전환된 효모로 부터 유도된 면역원성 HBsAg
US4683294A (en) 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
EP0278940A3 (en) 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis b virus surface antigens and hybrid antigens containing them
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
EP0314240A3 (en) 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
AU657168B2 (en) 1991-09-18 1995-03-02 Amgen, Inc. Hepatitis B vaccine with bile salt adjuvant
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
NZ295998A (en) * 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
HUP0101047A3 (en) * 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
EP1140155A4 (en) * 1998-12-23 2004-11-03 Merck & Co Inc IMPROVED RECOMBINATION HEPATITIS B ENVELOPE ANTIGEN
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Also Published As

Publication number Publication date
SK288079B6 (sk) 2013-06-03
BG66038B1 (bg) 2010-11-30
EG25829A (en) 2012-09-02
PL204736B1 (pl) 2010-02-26
EP1666487B1 (en) 2008-10-29
CA2427475C (en) 2011-07-05
US8624004B2 (en) 2014-01-07
UY26882A1 (es) 2002-03-22
PT1666487E (pt) 2008-12-26
HU228932B1 (en) 2013-06-28
SI1307473T1 (sl) 2006-04-30
SK1692003A3 (en) 2003-08-05
JP2012255015A (ja) 2012-12-27
AU8207301A (en) 2002-02-18
EP1307473A1 (en) 2003-05-07
HK1056884A1 (en) 2004-03-05
JP5559847B2 (ja) 2014-07-23
SK288069B6 (sk) 2013-05-03
PL362322A1 (en) 2004-10-18
HUP0302951A3 (en) 2004-10-28
BR0113155A (pt) 2003-07-08
AP2003002734A0 (en) 2003-03-31
NO20030635D0 (no) 2003-02-07
CZ2003385A3 (cs) 2003-06-18
EA006433B1 (ru) 2005-12-29
MY128999A (en) 2007-03-30
KR100804922B1 (ko) 2008-02-20
NO20030635L (no) 2003-04-01
ES2314555T3 (es) 2009-03-16
US20090123496A1 (en) 2009-05-14
SI1666487T1 (sl) 2009-02-28
BRPI0113155B1 (pt) 2018-11-21
CN1468256B (zh) 2010-10-27
DK1666487T3 (da) 2009-01-12
ATE412665T1 (de) 2008-11-15
CN1468256A (zh) 2004-01-14
DE60136400D1 (de) 2008-12-11
WO2002012287A1 (en) 2002-02-14
MXPA03001235A (es) 2004-07-16
CA2427475A1 (en) 2002-02-11
BRPI0113155C1 (pt) 2021-05-25
DE60116107D1 (de) 2006-01-26
KR20030029127A (ko) 2003-04-11
EP1307473B1 (en) 2005-12-21
BG107545A (bg) 2004-01-30
EP1666487A1 (en) 2006-06-07
DE60116107T2 (de) 2006-08-03
NZ524012A (en) 2004-02-27
AU2001282073B2 (en) 2005-01-20
JP2004505992A (ja) 2004-02-26
OA12361A (en) 2004-04-13
US20060159705A1 (en) 2006-07-20
UA79735C2 (uk) 2007-07-25
IL154301A0 (en) 2003-09-17
PE20020287A1 (es) 2002-06-20
DZ3470A1 (fr) 2002-02-14
ATE313558T1 (de) 2006-01-15
BRPI0113155B8 (pt) 2019-08-13
CZ303217B6 (cs) 2012-05-30
IL154301A (en) 2009-11-18
CY1106310T1 (el) 2011-10-12
CA2740282A1 (en) 2002-02-11
US20030235590A1 (en) 2003-12-25
CY1108789T1 (el) 2014-04-09
ES2254464T3 (es) 2006-06-16
EA200300129A1 (ru) 2003-10-30
DK1307473T3 (da) 2006-05-01
AR030325A1 (es) 2003-08-20

Similar Documents

Publication Publication Date Title
HUP0302951A2 (hu) Eljárás HBV antigének tisztítására, vakcinákban történő alkalmazásra
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
HUP0102478A2 (hu) A HCV-burokfehérjék által alkotott részecskék alkalmazása vakcinázásban
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
EP1504112A4 (en) DEVELOPMENT OF A VACCINE FOR THE PREVENTION OF INFECTIONS WITH THE FILOVIRUS IN PRIMATES
HK1081207A1 (en) Hbv precore protein capable of forming particles
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
SE9903534D0 (sv) Vaccin
DE50106464D1 (de) Verfahren zur reinigung von 2-chlor-5-chlormethylthiazol
ECSP034474A (es) Nuevo tratamiento
DE60013242D1 (de) Impfungsmethode zur effizienten induktion der t-lymphozyten zytotoxischantwort
WO2000062803A3 (en) ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees